Refine
Year of publication
Language
- English (45)
Has Fulltext
- yes (45)
Is part of the Bibliography
- no (45)
Keywords
- Genetics (2)
- Health care (2)
- Multimorbidity (2)
- Multiple chronic conditions (2)
- Polypharmacy (2)
- AML (1)
- ATG8 (1)
- Adhesion (1)
- Advanced breast cancer (1)
- Antihormone therapy (1)
- Autophagy (1)
- BG-index (1)
- Biochemistry (1)
- Bipolar disorder (1)
- Breast cancer (1)
- COVID-19 (1)
- CVID (1)
- CXCL12 (1)
- CXCR4 (1)
- Cardiology (1)
- Clinical variation (1)
- Completed suicide (1)
- Depression (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Elderly (1)
- European Society for Immunodeficiencies (ESID) (1)
- Frailty (1)
- GABARAP (1)
- General practice (1)
- General practitioners (1)
- Genome-wide association studies (1)
- German PID-NET registry (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- Health services (1)
- Heregulin (1)
- Hypertension (1)
- IgG substitution therapy (1)
- Immunology (1)
- KCGS (1)
- LC3 (1)
- MACE (1)
- MM-121 (1)
- Medication changes (1)
- Metastatic (1)
- NPM1 (1)
- NPM1c (1)
- NXF1 (1)
- Neuroscience (1)
- Older adults (1)
- Oldest-old (1)
- Oncology (1)
- PID prevalence (1)
- Pandemic (1)
- Patients (1)
- Population-based screening (1)
- Primary health care (1)
- RNA Biology (1)
- Recall rate (1)
- Red blood cell transfusion (1)
- SARS-CoV-2 (1)
- SARS-CoV2 (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- Seribantumab (1)
- Suicide attempt (1)
- T-DM1 (1)
- TFEB (1)
- Viral infection (1)
- academic medicine (1)
- advanced breast cancer (1)
- alternative 3′ end processing (1)
- anaemia (1)
- antihormone therapy (1)
- atherosclerosis (1)
- atypical LIR (1)
- cardiovascular disease (1)
- career promotion (1)
- chemogenomic set (1)
- chemotherapy (1)
- collaborative healthcare (1)
- drug discovery (1)
- druggable genome (1)
- economic outcomes (1)
- elderly patients (1)
- epigenetics (1)
- gender difference (1)
- health service utilisation (1)
- hemodialysis (1)
- iCLIP (1)
- integrins (1)
- iron deficiency (1)
- kidney disease (1)
- kinase inhibitor (1)
- lapatinib (1)
- lysosome (1)
- mRNA export (1)
- medical error (1)
- metastatic (1)
- miRNA (1)
- multivariable analysis (1)
- next-generation sequencing (1)
- osteoarthritis (1)
- patient blood management (1)
- patient safety (1)
- pertuzumab (1)
- phenotypic screening (1)
- preoperative anaemia management (1)
- primary health care (1)
- primary immunodeficiency (PID) (1)
- promotion index (1)
- prostate carcinoma cells (1)
- protein kinase (1)
- registry for primary immunodeficiency (1)
- risk management (1)
- small molecules (1)
- surgery (1)
- trastuzumab (1)
- understudied kinase (1)
Institute
- Medizin (45) (remove)
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.
The demand to develop convergent technology platforms, such as bio-functionalized medical devices, is rapidly increasing. However, the loss of biological function of the effector molecules during sterilization represents a significant and general problem. Therefore, we have developed and characterized a nano-coating (NC) formulation capable of maintaining the functionality of proteins on biological-device combination products. As a proof of concept, the NC preserved the structural and functional integrity of an otherwise highly fragile antibody immobilized on polyurethane during deleterious sterilizing irradiation (≥ 25 kGy). The NC procedure enables straight-forward terminal sterilization of bio-functionalized materials while preserving optimal conditioning of the bioactive surface.
Highlights
• NPM1/NPM1c induce the autophagy-lysosome pathway by activating the master regulator TFEB
• NPM1/NPM1c bind to GABARAP proteins via an atypical module in their N-terminal regions
• The pro-autophagic activity of NPM1c depends on this GABARAP binding module
Summary
The nucleolar scaffold protein NPM1 is a multifunctional regulator of cellular homeostasis, genome integrity, and stress response. NPM1 mutations, known as NPM1c variants promoting its aberrant cytoplasmic localization, are the most frequent genetic alterations in acute myeloid leukemia (AML). A hallmark of AML cells is their dependency on elevated autophagic flux. Here, we show that NPM1 and NPM1c induce the autophagy-lysosome pathway by activating the master transcription factor TFEB, thereby coordinating the expression of lysosomal proteins and autophagy regulators. Importantly, both NPM1 and NPM1c bind to autophagy modifiers of the GABARAP subfamily through an atypical binding module preserved within its N terminus. The propensity of NPM1c to induce autophagy depends on this module, likely indicating that NPM1c exerts its pro-autophagic activity by direct engagement with GABARAPL1. Our data report a non-canonical binding mode of GABARAP family members that drives the pro-autophagic potential of NPM1c, potentially enabling therapeutic options.
Objective: To evaluate a novel healthcare programme for the treatment of patients with hip and knee osteoarthritis in southern Germany in terms of clinical and health economic outcomes. The study is based on claims data from 2014 to 2017.
Methods: We conducted a retrospective comparative cohort study of 9768 patients with hip and knee osteoarthritis, of whom 9231 were enrolled in a collaborative ambulatory orthopaedic care programme (intervention group), and 537 patients received usual orthopaedic care (control group). Key features of the programme are coordinated care, morbidity-adapted reimbursement and extended consultation times. Multivariable analysis was performed to determine effects on health utilisation outcomes. The economic analysis considered annual costs per patient from a healthcare payer perspective, stratified by healthcare service sector. Besides multivariable regression analyses, bootstrapping was used to estimate confidence intervals for predicted mean costs by group.
Results: Musculoskeletal-disease-related hospitalisation was much less likely among intervention group patients than control group patients [odds ratio (OR): 0.079; 95% CI: 0.062–0.099]. The number of physiotherapy prescriptions per patient was significantly lower in the intervention group (RR: 0.814; 95% CI: 0.721–0.919), while the likelihood of participation in exercise programmes over one year was significantly higher (OR: 3.126; 95% CI: 1.604–6.094). Enrolment in the programme was associated with significantly higher ambulatory costs (€1048 vs. €925), but costs for inpatient care, including hospital stays, were significantly lower (€1003 vs. €1497 and €928 vs. €1300 respectively). Overall annual cost-savings were €195 per patient.
Conclusions: Collaborative ambulatory orthopaedic care was associated with reduced hospitalisation in patients with hip and knee osteoarthritis. Health costs for programme participants were lower overall, despite higher costs for ambulatory care.
Calreticulin is a Ca2+ -binding chaperone that resides in the lumen of the endoplasmic reticulum and is involved in the regulation of intracellular Ca2+ homeostasis and in the folding of newly synthesized glycoproteins. In this study, we have used site-specific mutagenesis to map amino acid residues that are critical in calreticulin function. We have focused on two cysteine residues (Cys(88) and Cys(120)), which form a disulfide bridge in the N-terminal domain of calreticulin, on a tryptophan residue located in the carbohydrate binding site (Trp(302)), and on certain residues located at the tip of the "hairpin-like" P-domain of the protein (Glu(238), Glu(239), Asp(241), Glu(243), and Trp(244)). Calreticulin mutants were expressed in crt(-/-) fibroblasts, and bradykinin-dependent Ca2+ release was measured as a marker of calreticulin function. Bradykinin-dependent Ca2+ release from the endoplasmic reticulum was rescued by wild-type calreticulin and by the Glu(238), Glu(239), Asp(241), and Glu(243) mutants. The Cys(88) and Cys(120) mutants rescued the calreticulin-deficient phenotype only partially ( approximately 40%), and the Trp(244) and Trp(302) mutants did not rescue it at all. We identified four amino acid residues (Glu(239), Asp(241), Glu(243), and Trp(244)) at the hairpin tip of the P-domain that are critical in the formation of a complex between ERp57 and calreticulin. Although the Glu(239), Asp(241), and Glu(243) mutants did not bind ERp57 efficiently, they fully restored bradykinin-dependent Ca2+ release in crt(-/-) cells. This indicates that binding of ERp57 to calreticulin may not be critical for the chaperone function of calreticulin with respect to the bradykinin receptor.